MedTrace Logo

Nebulized Albuterol for Congestive Heart Failure Exacerbation

NCT01375361 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2013-10-10

No results posted yet for this study

Summary

This is a randomized trial of the use of Albuterol in the setting of acute decompensated Congestive Heart Failure with radiographic evidence of Cardiogenic Pulmonary Edema.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Albuterol

2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.

DRUG

Normal Saline

2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.

Sponsors & Collaborators

Principal Investigators

  • John C. Stein, MD. · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01375361 on ClinicalTrials.gov